Table 8.
Results of anti-SARS-CoV-2 testing. Note: ‘Very wide’ means some activity was observed at high concentrations too staggering to plot.
| Test compound | IC50_Viral Entry blocking assay (µM) | Percent inhibition at 50 µM (%) | IC-50_Viral Spread assay (µM) | Percent inhibition at 50 µM (%) | Cytotoxicity (µM) | Predicted Target(s) |
|---|---|---|---|---|---|---|
| *Bisindolylmaleimide IX | 28.18 | 80 | 381.5 | 15 | Nontoxic within tested conc. range | 3CLpro and ExoN |
| Ivermectin | 2.702 | 99 | 6.015 | 46 | Toxic above 50 | Probably Helicase |
| *Haloperidol | (Very wide) | 10 | (Very wide) | 03 | Non-toxic within tested conc. range | NendoU and 3CLpro |
| Troxerutin | (Very wide) | 11 | (Very wide) | 03 | Nontoxic within tested conc. range | 3CLpro and PLpro |
| Amikacin hydrate | (Very wide) | 08 | (Very wide) | 03 | Nontoxic within tested conc. range | RdRP |
| Paromomycin | ∼99.86 | 05 | (Very wide) | 02 | Nontoxic within tested conc. range | RdRP |
| Lactulose | nil | 01 | nil | 03 | Nontoxic within tested conc. range | RdRP |
| Iopromide | nil | 02 | nil | 02 | Nontoxic within tested conc. range | 3CLpro |
NT, Not tested
* Targets validated.
* Compounds with validated MOA through in-vitro assay.